
### [MONDO:0018881](http://purl.obolibrary.org/obo/MONDO_0018881)
**Label:** myelodysplastic syndrome

**Subclasses:** [MONDO:0019454](http://purl.obolibrary.org/obo/MONDO_0019454) (refractory anemia with excess blasts), [MONDO:0019453](http://purl.obolibrary.org/obo/MONDO_0019453) (refractory cytopenia with multilineage dysplasia), [MONDO:0013667](http://purl.obolibrary.org/obo/MONDO_0013667) (myelodysplastic syndrome), 

**Corr. equiv. classes:** [Orphanet:86839](http://www.orpha.net/ORDO/Orphanet_86839), [Orphanet:86836](http://www.orpha.net/ORDO/Orphanet_86836), [Orphanet:52688](http://www.orpha.net/ORDO/Orphanet_52688), [OMIM:614286](http://purl.obolibrary.org/obo/OMIM_614286), 

**Class expressions from DL-Learner:**

- [HP:0001428](http://purl.obolibrary.org/obo/HP_0001428) (Somatic mutation) and [HP:0002863](http://purl.obolibrary.org/obo/HP_0002863) (Myelodysplasia) 62.50%
- [HP:0001428](http://purl.obolibrary.org/obo/HP_0001428) (Somatic mutation) and [HP:0002863](http://purl.obolibrary.org/obo/HP_0002863) (Myelodysplasia) and (not ([HP:0002715](http://purl.obolibrary.org/obo/HP_0002715) (Abnormality of the immune system))) 62.50%
- [HP:0000005](http://purl.obolibrary.org/obo/HP_0000005) (Mode of inheritance) and [HP:0002863](http://purl.obolibrary.org/obo/HP_0002863) (Myelodysplasia) and (not ([HP:0002715](http://purl.obolibrary.org/obo/HP_0002715) (Abnormality of the immune system))) 62.50%
- [HP:0002863](http://purl.obolibrary.org/obo/HP_0002863) (Myelodysplasia) and (not ([HP:0002715](http://purl.obolibrary.org/obo/HP_0002715) (Abnormality of the immune system))) 47.86%
- [HP:0002863](http://purl.obolibrary.org/obo/HP_0002863) (Myelodysplasia) and (not ([HP:0010987](http://purl.obolibrary.org/obo/HP_0010987) (Abnormality of cellular immune system))) 37.50%
- [HP:0002863](http://purl.obolibrary.org/obo/HP_0002863) (Myelodysplasia) and (not ([HP:0001881](http://purl.obolibrary.org/obo/HP_0001881) (Abnormality of leukocytes))) 37.50%
- [HP:0001428](http://purl.obolibrary.org/obo/HP_0001428) (Somatic mutation) and [HP:0004377](http://purl.obolibrary.org/obo/HP_0004377) (Hematological neoplasm) 32.91%
- [HP:0000005](http://purl.obolibrary.org/obo/HP_0000005) (Mode of inheritance) and [HP:0002863](http://purl.obolibrary.org/obo/HP_0002863) (Myelodysplasia) 31.40%
- [HP:0001428](http://purl.obolibrary.org/obo/HP_0001428) (Somatic mutation) and [HP:0001871](http://purl.obolibrary.org/obo/HP_0001871) (Abnormality of blood and blood-forming tissues) 29.17%
- [HP:0002863](http://purl.obolibrary.org/obo/HP_0002863) (Myelodysplasia) 25.41%
- [HP:0001428](http://purl.obolibrary.org/obo/HP_0001428) (Somatic mutation) and [HP:0002664](http://purl.obolibrary.org/obo/HP_0002664) (Neoplasm) 23.16%
- [HP:0000118](http://purl.obolibrary.org/obo/HP_0000118) (Phenotypic abnormality) and [HP:0001428](http://purl.obolibrary.org/obo/HP_0001428) (Somatic mutation) 21.95%
- [HP:0001428](http://purl.obolibrary.org/obo/HP_0001428) (Somatic mutation) 21.78%
- [HP:0004377](http://purl.obolibrary.org/obo/HP_0004377) (Hematological neoplasm) 18.39%
- [HP:0011793](http://purl.obolibrary.org/obo/HP_0011793) (Neoplasm by anatomical site) 14.99%


